Login to Your Account



Earnings Miss, but Stock Gains 9%

Cubist Pharmaceuticals' Phase III Trials Squaring Off Against Pain, Constipation

By Randy Osborne
Staff Writer

Monday, July 22, 2013
Cubist Pharmaceuticals Inc. followed up its earnings tally with word that the first patient has joined the 1 ,800-patient Phase III program called ASCENT with bevenopran, previously known as CB-5945, a peripherally active mu opioid receptor antagonist for chronic noncancer pain and opioid-induced constipation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription